Paul Hudson, Sanofi CEO (Jeremy Paoloni/Abaca/Sipa USA/Sipa via AP Images)

FTC ex­pands phar­ma scruti­ny to ear­ly-stage deals, forc­ing Sanofi to drop Pompe dis­ease part­ner­ship with Maze

The Fed­er­al Trade Com­mis­sion said it would seek to block Sanofi’s pro­posed li­cens­ing deal for Maze Ther­a­peu­tics’ clin­i­cal-stage Pompe dis­ease treat­ment, lead­ing the French phar­ma to say it would back out of the agree­ment.

Sanofi al­ready mar­kets Nexvi­azyme, a suc­ces­sor to its own My­ozyme/Lu­mizyme, and the US reg­u­la­tor said Mon­day that the up to $755 mil­lion pro­posed deal “would elim­i­nate a nascent com­peti­tor poised to chal­lenge Sanofi’s mo­nop­oly in the Pompe dis­ease ther­a­py mar­ket.” The agency au­tho­rized a law­suit in fed­er­al court, it said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.